| Title |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, November 2017
|
| DOI | 10.1002/cpt.911 |
| Pubmed ID | |
| Authors |
Ursula Amstutz, Linda M. Henricks, Steven M. Offer, Julia Barbarino, Jan H.M. Schellens, Jesse J. Swen, Teri E. Klein, Howard L. McLeod, Kelly E. Caudle, Robert B. Diasio, Matthias Schwab |
| Abstract |
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC(®) ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/). |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 23% |
| Mexico | 1 | 8% |
| Venezuela, Bolivarian Republic of | 1 | 8% |
| Unknown | 8 | 62% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 77% |
| Practitioners (doctors, other healthcare professionals) | 3 | 23% |
Mendeley readers
The data shown below were compiled from readership statistics for 407 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 407 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 54 | 13% |
| Student > Master | 53 | 13% |
| Researcher | 44 | 11% |
| Student > Ph. D. Student | 35 | 9% |
| Student > Postgraduate | 21 | 5% |
| Other | 58 | 14% |
| Unknown | 142 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 85 | 21% |
| Biochemistry, Genetics and Molecular Biology | 66 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 57 | 14% |
| Agricultural and Biological Sciences | 15 | 4% |
| Chemistry | 8 | 2% |
| Other | 23 | 6% |
| Unknown | 153 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2022.
All research outputs
#1,627,850
of 25,837,817 outputs
Outputs from Clinical Pharmacology & Therapeutics
#232
of 4,619 outputs
Outputs of similar age
#35,528
of 450,176 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#4
of 71 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,619 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,176 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.